Incidence of ROS1-Rearranged Non-Small-Cell Lung Carcinoma in India and Efficacy of Crizotinib in Lung Adenocarcinoma Patients

Código QR

Incidence of ROS1-Rearranged Non-Small-Cell Lung Carcinoma in India and Efficacy of Crizotinib in Lung Adenocarcinoma Patients

Anurag Mehta, 1 Mumtaz Saifi, 2 Ullas Batra, 3 M Suryavanshi, 2 Kush Gupta 4 1Laboratory Services, Rajiv Gandhi Cancer Institute and Research Centre, New Delhi, India; 2Department of Molecular Pathology, Rajiv Gandhi Cancer Institute and Research Centre, New Delhi, India; 3Medical Oncology, Rajiv...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Mehta A, Saifi M, Batra U, Suryavanshi M, Gupta K
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2020
Materias:	nsclc ros 1 crizotinib Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/399af9303b5a4cea8b3c79464c26f7a1
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Rapidly Destructive Coxarthrosis as a Potential Side Effect of Crizotinib in a Patient with ROS1-Positive Lung Adenocarcinoma
por: Takamori S, et al.
Publicado: (2020)

Small cell transformation in crizotinib‐resistant ROS1‐rearranged non‐small cell lung cancer with retention of ROS1 fusion: A case report
por: Chi‐Hao Wu, et al.
Publicado: (2021)

Spotlight on crizotinib in the first-line treatment of ALK-positive advanced non-small-cell lung cancer: patients selection and perspectives
por: Giroux Leprieur E, et al.
Publicado: (2016)

Hexokinases II‐mediated glycolysis governs susceptibility to crizotinib in ALK‐positive non‐small cell lung cancer
por: Caiyu Lin, et al.
Publicado: (2021)

Differential response to a combination of full-dose osimertinib and crizotinib in a patient with EGFR-mutant non-small cell lung cancer and emergent MET amplification
por: Zhu VW, et al.
Publicado: (2019)

Spotlight on brigatinib and its potential in the treatment of patients with metastatic ALK-positive non-small cell lung cancer who are resistant or intolerant to crizotinib
por: Jain RK, et al.
Publicado: (2017)

Hepatoid adenocarcinoma of the lung: An analysis of the Surveillance, Epidemiology, and End Results (SEER) database
por: Lei Lei, et al.
Publicado: (2021)

Detection of ROS1 rearrangement in non-small cell lung cancer: current and future perspectives
por: Rossi G, et al.
Publicado: (2017)

Genomic landscape of metastatic lung adenocarcinomas from large-scale clinical sequencing
por: Dingbiao Li, et al.
Publicado: (2021)

Small cell lung cancer transformation during antitumor therapies: A systematic review
por: Chai Xing, et al.
Publicado: (2021)

Polycaprolactone Electrospun Scaffolds Produce an Enrichment of Lung Cancer Stem Cells in Sensitive and Resistant EGFRm Lung Adenocarcinoma
por: Emma Polonio-Alcalá, et al.
Publicado: (2021)

AKF-D52, a Synthetic Phenoxypyrimidine-Urea Derivative, Triggers Extrinsic/Intrinsic Apoptosis and Cytoprotective Autophagy in Human Non-Small Cell Lung Cancer Cells
por: Hyo-Sun Gil, et al.
Publicado: (2021)

The prognostic landscape of genes and infiltrating immune cells in cytokine induced killer cell treated-lung squamous cell carcinoma and adenocarcinoma
por: Jian Wang, et al.
Publicado: (2021)

ROS-induced dramatic lipid changes in Arabidopsis
por: Tianlin Jin, et al.
Publicado: (2021)

Prognostic value of microRNA-4521 in non-small cell lung cancer and its regulatory effect on tumor progression
por: Sun Butong, et al.
Publicado: (2021)

Astilbin reduces ROS accumulation and VEGF expression through Nrf2 in psoriasis-like skin disease
por: Wang,Wuyuntana, et al.
Publicado: (2019)

Identification of circRNA_001846 as putative non–small cell lung cancer biomarker
por: Fan Yang, et al.
Publicado: (2021)

Clinical utility of ramucirumab in non-small-cell lung cancer
por: Uprety D
Publicado: (2019)

The role of ferroptosis in lung cancer
por: Sikai Wu, et al.
Publicado: (2021)

Role of afatinib in the treatment of advanced lung squamous cell carcinoma
por: Vavalà T
Publicado: (2017)

Recognizing Prognostic and Predictive Biomarkers in the Treatment of Non-Small Cell Lung Cancer (NSCLC) with Immune Checkpoint Inhibitors (ICIs)
por: Giustini N, et al.
Publicado: (2021)

Lotus leaf flavonoids induce apoptosis of human lung cancer A549 cells through the ROS/p38 MAPK pathway
por: Jia,Xiang-Bo, et al.
Publicado: (2021)

Clinical use of crizotinib for the treatment of non-small cell lung cancer
por: Roberts PJ
Publicado: (2013)

Clinical Management and Outcome of Grade III Pneumonitis after Chemoradioimmunotherapy for Inoperable Stage III Non-Small Cell Lung Cancer—A Prospective Longitudinal Assessment
por: Diego Kauffmann-Guerrero, et al.
Publicado: (2021)

Endostar (rh‐endostatin) improves efficacy of concurrent chemoradiotherapy for locally advanced non‐small cell lung cancer: A systematic review and meta‐analysis
por: Meng Yuan, et al.
Publicado: (2021)

Validation of liquid biopsy: plasma cell-free DNA testing in clinical management of advanced non-small cell lung cancer
por: Veldore VH, et al.
Publicado: (2018)

Efficacy and safety of MIL60 compared with bevacizumab in advanced or recurrent non-squamous non-small cell lung cancer: a phase 3 randomized, double-blind study
por: Rui Wan, et al.
Publicado: (2021)

Clinicopathological and prognostic implications of ALK rearrangement in patients with completely surgically resected lung adenocarcinoma
por: Huan Zhang, et al.
Publicado: (2021)

Identification of lncRNA–miRNA–mRNA Networks Linked to Non-small Lung Cancer Resistance to Inhibitors of Epidermal Growth Factor Receptor
por: Ting Wang, et al.
Publicado: (2021)

Role of Rho Guanine Nucleotide Exchange Factors in Non-Small Cell Lung Cancer
por: Rui-Jie Zeng, et al.
Publicado: (2021)

Identification and Validation of an Immune and Ferroptosis-Combined Index for Non–Small Cell Lung Cancer
por: Yang Teng, et al.
Publicado: (2021)

Elemene Nanoemulsion Inhibits Metastasis of Breast Cancer by ROS Scavenging
por: Han B, et al.
Publicado: (2021)

Combination pembrolizumab plus chemotherapy: a new standard of care for patients with advanced non-small-cell lung cancer
por: Weinberg F, et al.
Publicado: (2019)

Crizotinib-induced immunogenic cell death in non-small cell lung cancer
por: Peng Liu, et al.
Publicado: (2019)

ALK and IGF-1R as independent targets in crizotinib resistant lung cancer
por: Christabel Wilson, et al.
Publicado: (2017)

Isolation of Mitochondria From Fresh Mice Lung Tissue
por: Dayene de Assis Fernandes Caldeira, et al.
Publicado: (2021)

The Immune Landscape of Human Primary Lung Tumors Is Th2 Skewed
por: Astri Frafjord, et al.
Publicado: (2021)

miRNA-21 as a novel therapeutic target in lung cancer
por: Markou A, et al.
Publicado: (2016)

Spotlight on ramucirumab in the treatment of nonsmall cell lung cancer: design, development, and clinical activity
por: Cobo M, et al.
Publicado: (2017)

Impacts of exogenous ROS scavenger ascorbic acid on the storability and quality attributes of fresh longan fruit
por: Jingyun Liu, et al.
Publicado: (2021)